Recent Trends in GLP-1 Use and Spending in Medicare Ahead of the Trump administrations planned expansion of Medicare coverage for GLP-1s to treat obesity through temporary models and the availability of Medicares negotiated price for certain GLP-1 products beginning in 2027, this analysis examines CMSs Medicare Part D claims data from 2019 to 2024 to document the increase in the number of beneficiaries being treated with GLP-1 drugs and the growth in Medicare spending and claims for these drugs
doi:10.1016/0016-6480(89)90066-X Return to citation in text: [1] Ying, J
In the subgroup of patients not receiving SGLT-2 inhibitors at baseline, semaglutide was associated with a statistically significant reduction in risk of the primary endpoint of 27% (hazard ratio 0.73, 95% confidence interval 0.630.85)
Join our mailing list to stay up to date on whats happening at NurseCE4Less and make sure you never miss a deadline!
Plant Sci 166:687694 Tewari RK, Kumar P, Neetu SPN (2005) Signs of oxidative stress in the chlorotic leaves of iron starved plants
How PlexusDx Supports a More Personalized Approach PlexusDx genetic insights may help provide context for how your individual metabolic pathways respond to semaglutide, which can inform discussions about treatment stability and readiness for plasma donation
